Study of the Gut Hormone Analogue Y14 in Adult Subjects

Obesity Clinical Trial

Official title:

A Randomised, Placebo Controlled First in Human Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Y14 in Adult Subjects

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03673111
• Other study ID #: 2016/Y14/01
• Secondary ID: 2017-000380-33
• Status: Completed
• Phase: Phase 1
• Start date: May 10, 2017
• Est. completion date: December 24, 2018

Study information

• Verified date: January 2019
• Source: Imperial College London
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

A randomised, placebo controlled Phase I study to investigate investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of Y14 in adult subjects.

Description:

Objectives:

Primary Objective

• To investigate the safety and tolerability of single doses of Y14 in overweight/obese but otherwise healthy male subjects.

• To investigate the safety and tolerability of multiple doses of Y14 in overweight/obese male subjects with normal glucose tolerance, Type 2 diabetes or prediabetes.

Secondary Objectives

• To assess the pharmacokinetic (PK) profile of single doses of Y14 in overweight/obese but otherwise healthy male subjects.

• To assess the PK profile of multiple ascending doses of Y14 in overweight/obese male subjects with normal glucose tolerance, Type 2 diabetes or prediabetes.

Exploratory Objective

• To investigate the effects of multiple doses of Y14 on food consumption, body weight, enteropancreatic hormone changes and glucose tolerance in overweight/obese male subjects with normal glucose tolerance, Type 2 diabetes or prediabetes.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 77
• Est. completion date: December 24, 2018
• Est. primary completion date: December 24, 2018
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Male
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

1. Adult males aged 18 to 65 years inclusive with BMI between 25.0 and 38.0 kg/m2 inclusive;

2. (PART B only) Subjects who have normal glucose tolerance, Type 2 diabetes, impaired glucose tolerance or impaired fasting glucose according to WHO 2006 and 2011 criteria;

3. Subjects who are otherwise healthy enough to participate, as determined by pre-study medical history, physical examination and 12-lead ECG;

4. Subjects whose clinical laboratory test results are either within the normal range or if outside this range the abnormalities are judged to be not clinically relevant and are acceptable to the Investigator;

5. Subjects who are negative for hepatitis B surface antigen (HBsAg), hepatitis C antibody and human immunodeficiency virus (HIV) I and II tests at screening;

6. Subjects who are negative for drugs of abuse and alcohol tests at screening and admissions;

7. Subjects who are non-smokers for at least 3 months preceding screening;

8. Subjects who agree to use medically acceptable methods of contraception for at least 3 months after study drug administration;

9. Subjects who agree not to donate sperm for at least 3 months after study drug administration;

10. Subjects who are able and willing to give written informed consent.

Exclusion Criteria:

1. Subjects who do not conform to the above inclusion criteria;

2. Subjects who have a clinically relevant history or presence of gastrointestinal (especially associated with vomiting), respiratory, renal, hepatic, haematological, lymphatic, neurological (especially if associated with balance disorders or vomiting e.g. migraine or labyrinthitis), cardiovascular, psychiatric, musculoskeletal, genitourinary, immunological, dermatological, connective tissue diseases or disorders;

3. Subjects who have a clinically relevant surgical history;

4. Subjects who are currently taking any of the following classes of diabetes medications: thiazolidinediones, dipeptidyl peptidase IV inhibitors ('gliptins'), GLP-1 analogues, and insulin;

5. Subjects who have a history of relevant and severe atopy e.g. asthma, angioedema requiring emergency treatment, severe hayfever requiring regular treatment (i.e. taking antihistamines and/or glucorticoids more regularly than 3 times a week), severe eczema requiring regular treatment (i.e. taking antihistamines and/or glucocorticoids more regularly than 3 times a week);

6. Subjects who have a history of relevant drug hypersensitivity;

7. Subjects who have a history of alcohol abuse or alcohol dependence according to DSMIV criteria within the last 2 years;

8. Subjects who have a history of drug or substance abuse according to DSM-IV criteria within the last 2 years;

9. Subjects who have a history of clinically significant migraine as judged by the Investigator. Subjects can be included if they have not had a migraine for the last 3 years;

10. Subjects with a history of pancreatitis or pancreatic cancer;

11. Subjects who consume more than 21 units of alcohol a week (unit = 1 glass of wine (125 mL) = 1 measure of spirits = ½ pint of beer);

12. Subjects who have a significant infection or known inflammatory process on screening;

13. Subjects who have acute gastrointestinal symptoms at the time of screening or admission (e.g. nausea, vomiting, diarrhoea, heartburn);

14. Subjects who have an acute infection such as influenza at the time of screening or admission;

15. Subjects who have used prescription drugs within 2 weeks of first dosing. For Part B, patients are allowed to be treated for their diabetes with monotherapy with a sulphonylurea, metformin, or a SGLT-2 inhibitor, dual therapy with any two of the following drug types: a sulphonylurea, metformin, and/or a SGLT-2 inhibitor; triple therapy with a sulphonylurea, metformin, and a SGLT-2 inhibitor. In addition patients in Part B are allowed to take hypolipidaemic and/or antihypertensive treatments, provided that the doses have not been altered within the 4 weeks prior to entering the study. Other medications may be allowed if the Investigator and Sponsor both agree that they will not affect the outcome of the study or the safety of the subject.

16. Subjects who have used over the counter medication excluding routine vitamins and paracetamol but including megadose (intake of 20 to 600 times the recommended daily dose) vitamin therapy within 7 days of first dosing, unless agreed as not clinically relevant by the Principal Investigator and Sponsor;

17. Subjects who have donated blood within 3 months prior to screening; Subjects who have donated plasma within the 7 days prior to screening; Subjects who have donated platelets within the 6 weeks prior to screening

18. Subjects who have used any investigational drug in any clinical trial within 3 months of their first admission date;

19. Subjects who have received the last dose of investigational drug greater than 3 months ago but who are on extended follow-up;

20. Subjects who have previously received Y14;

21. Subjects who are vegans, vegetarian or have any dietary restriction (unless agreed as not clinically relevant by the PI and Sponsors);

22. Subjects who cannot communicate reliably with the Investigator;

23. Subjects who are unlikely to co-operate with the requirements of the study;

24. History or evidence of abnormal eating behaviour, as observed through the Dutch Eating Behaviour (DEBQ) and SCOFF questionnaires at screening.

Related Conditions & MeSH terms

• Diabetes Mellitus
• Obesity

Intervention

Drug:
• Y14
Gut hormone analogue
• Placebo
0.9% saline

Locations

Country	Name	City	State
United Kingdom	Covance Clinical Research Unit	Leeds

Sponsors (3)

Lead Sponsor	Collaborator
Imperial College London	Covance, Medical Research Council

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Incidence of Treatment-Emergent Adverse Events (safety and tolerability)	Count of events	Up to 73 days after dosing
Secondary	Maximum observed drug concentrations	(Cmax)	Up to 4 days (72h) after dosing and follow-up
Secondary	Time of occurrence of Cmax	(tmax)	Up to 4 days (72h) after dosing and follow-up
Secondary	Area under the plasma concentration -time curves	(AUC)	Up to 4 days (72h) after dosing and follow-up
Secondary	Apparent terminal rate constant	?z	Up to 4 days (72h) after dosing and follow-up
Secondary	Apparent terminal half-life (t1/2)	t½	Up to 4 days (72h) after dosing and follow-up
Secondary	Visual analogue scale scoring as measures of satiety and nausea	% change from baseline	Up to 4 days (72h) after dosing
Secondary	Food intake	Assessed by measurement of weight of food eaten during meals supplied during in-patient phase of study	Up to 4 days (72h) after dosing
Secondary	Body weight	(kg)	Up to 73 days after dosing